Roger Jeffs Sells 29,976 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Roger Jeffs sold 29,976 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the completion of the sale, the director now owns 120,756 shares of the company’s stock, valued at approximately $8,416,693.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM traded up $5.80 during mid-day trading on Friday, reaching $75.54. 1,624,696 shares of the company’s stock were exchanged, compared to its average volume of 773,656. Axsome Therapeutics, Inc. has a one year low of $55.02 and a one year high of $98.40. The firm has a market capitalization of $3.58 billion, a PE ratio of -14.53 and a beta of 1.17. The business’s fifty day simple moving average is $85.56 and its two-hundred day simple moving average is $75.47. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.52 and a current ratio of 3.63.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Tuesday, February 20th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($1.21) by $0.48. Axsome Therapeutics had a negative net margin of 88.41% and a negative return on equity of 70.67%. The business had revenue of $71.53 million for the quarter, compared to analyst estimates of $70.38 million. Analysts anticipate that Axsome Therapeutics, Inc. will post -3.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Axsome Therapeutics

Several hedge funds have recently bought and sold shares of AXSM. JPMorgan Chase & Co. increased its holdings in Axsome Therapeutics by 0.5% in the 1st quarter. JPMorgan Chase & Co. now owns 176,086 shares of the company’s stock valued at $7,288,000 after buying an additional 843 shares during the period. Raymond James Financial Services Advisors Inc. bought a new position in Axsome Therapeutics in the 1st quarter valued at about $732,000. MetLife Investment Management LLC boosted its stake in shares of Axsome Therapeutics by 59.0% in the 1st quarter. MetLife Investment Management LLC now owns 17,348 shares of the company’s stock valued at $718,000 after purchasing an additional 6,439 shares in the last quarter. Panagora Asset Management Inc. acquired a new stake in shares of Axsome Therapeutics in the 1st quarter valued at approximately $526,000. Finally, Sei Investments Co. boosted its stake in shares of Axsome Therapeutics by 1.3% in the 1st quarter. Sei Investments Co. now owns 146,363 shares of the company’s stock valued at $6,059,000 after purchasing an additional 1,909 shares in the last quarter. 76.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

AXSM has been the subject of a number of recent analyst reports. Citigroup initiated coverage on shares of Axsome Therapeutics in a research note on Wednesday, December 13th. They issued a “buy” rating and a $125.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $180.00 price target on shares of Axsome Therapeutics in a research note on Monday, March 4th. Royal Bank of Canada cut their price target on shares of Axsome Therapeutics from $126.00 to $123.00 and set an “outperform” rating for the company in a research note on Wednesday, February 21st. Mizuho dropped their price objective on shares of Axsome Therapeutics from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Finally, Piper Sandler increased their price objective on shares of Axsome Therapeutics from $90.00 to $113.00 and gave the company an “overweight” rating in a research report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $116.10.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.